Abstract
Proton pump inhibitors are taken by millions of patients for prevention and treatment of gastroesophageal diseases. Case-control studies have suggested that use of omeprazole is associated with an increased risk of hip fractures. The aim of this prospective study was to assess the risk of vertebral fractures in postmenopausal women using omeprazole. We studied 1,211 postmenopausal women enrolled in the Osteoporosis and Ultrasound Study from the general population. Information on omeprazole and other risk factors for fractures including prevalent fractures and bone mineral density was obtained at baseline. Vertebral fractures were assessed on X-rays obtained at baseline and at the end of the 6-year follow-up and analyzed centrally. At baseline, 5% of this population was using omeprazole. Age-adjusted rates for vertebral fractures were 1.89 and 0.60 for 100 person-years for omeprazole users and nonusers, respectively (P = 0.009). In the multivariate analysis, omeprazole use was a significant and independent predictor of vertebral fractures (RR = 3.50, 95% CI 1.14–8.44). The other predictors were age higher than 65 years (RR = 2.34, 95% CI 1.02–5.34), prevalent vertebral fractures (RR = 3.62, 95% CI 1.63–8.08), and lumbar spine T score ≤ −2.5 (RR = 2.38, 95% CI 1.03–5.49). Omeprazole use is associated with an increased risk of vertebral fractures in postmenopausal women. Further studies are required to determine the mechanism of the association between the underlying gastric disease, omeprazole use, and risk of osteoporotic fractures.
References
Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC (2003) Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98:51–58
Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannel AJ et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338:727–734
Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg J et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 338:719–726
Chan FKL, Hung LCT, Suen BY, Wu JCY, Lee KC, Hui AJ et al (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110
Ekström P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G et al (1996) Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continous non-steroidal anti-inflammatory drug therapy. A nordic multicentre study. Scand J Gastroenterol 31:753–758
Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM et al (1998) Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 12:135–140
Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M (2002) Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 46:2195–2200
Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH et al (2002) Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346:2033–2038
Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonates use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57:813–816
Farina C, Gagliardi S (2002) Selective inhibition of osteoclast vacuolar H+-ATPase. Curr Pharm Des 8:2033–2048
Tuukkanen J, Vaananen HK (1986) Omeprazole, a specific inhibitor of H+-K+-ATPase inhibits bone resorption in vitro. Calcif Tissue Int 38:123–125
Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+-K−-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25
Baron R, Neff L, Louvard D, Courtoy PJ (1985) Cell-mediated extra-cellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of 100kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 101:2110–2222
Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S et al (2000) A selective inhibitor of the osteoclastic V–H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 106:309–318
Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83
Yang YN, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States 2005–2015. J Bone Miner Res 22:465–475
Glüer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R et al (2004) Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res 19:782–793
O’Neill TW, Cooper C, Cannata JB, Diaz Lopez JB, Hoszowski K, Johnell O et al (1994) Reproducibility of a questionnaire on risk factors for osteoporosis in a multicentre prevalence survey: the European Vertebral Osteoporosis Study. Int J Epidemiol 23:559–565
Mattsson JP, Vaananen K, Wallmark B, Lorentzon P (1991) Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H+-translocating ATPases. Biochim Biophys Acta 1065:261–268
Smith AN, Jouret F, Bord S, Borthwick KJ, Al-Lamki RS, Wagner CA et al (2005) Vacuolar H+-ATPase d2 subunit: molecular characterization, developmental regulation, and localization to specialized proton pumps in kidney and bone. J Am Soc Nephrol 16:1245–1256
Niikura K, Takano M, Sawada M (2004) A novel inhibitor of vacuolar ATPase, FR167356, can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol 142:558–566
Yu EW, Shinoff C, Blackwell T, Ensrud K, Hillier T, Bauer DC (2006) Use of acid-suppressive medications and risk of bone loss and fracture in postmenopausal women. J Bone Miner Res 21(Suppl 1):S281
Chonan O, Takahashi R, Yasui H, Watanuki M (1998) Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol 44:473–481
O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner U (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781
Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M et al (1995) Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 10:1376–1380
Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE et al (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14:364–368
Cumming RG (1990) Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 47:194–201
Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC et al (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–1628
Jackson RD, Lacroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al (2006) Calcium plus vitamin D supplementation and the risk of fracture. N Engl J Med 354:669–683
Koop H (1992) Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 6:399–406
Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, Kiel DP (2005) Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 20:152–158
Goerss JB, Kim CH, Atkinson EJ, Eastell R, O’Fallon WM, Melton LJ 3rd (1992) Risk of fractures in patients with pernicious anemia. J Bone Miner Res 7:573–579
McLean RR, Jacques PF, Selhub J et al (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042–2049
Hostmark AT (2003) Dietary acid load and self reported prevalence of hip fractures: a population based cross sectional study. Norsk Epidemiologi 13:193–198
Henriksen DB, Hartman B, Jeppesen PB, Miholic J, Christiansen C, Holst JJ (2004) The postprandial bone resorption process is regulated by gastrointestinal signal. J Bone Miner Res 19(Suppl 1):S92
Figura N, Gennari L, Merlotti D, Lenzi C, Campagna S, Franci B et al (2005) Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. Dig Dis Sci 5:847–852
Campbell-Thompson M, Reyher KK, Wilkinson LB (2001) Immunolocalization of estrogen receptor alpha and beta in gastric epithelium and enteric neurons. J Endocrinol 171:65–73
Ueyama T, Shirasawa N, Numazawa M, Yamada K, Shelangouski M, Ito T et al (2002) Gastric parietal cells: potent endocrine role in secreting estrogen as a possible regulator of gastro-hepatic axis. Endocrinology 143:3162–3170
Sozzi M, Valentini M, Figura N, De Paoli P, Tedeschi RM, Gloghini A et al (1998) Atrophic gastritis and intestinal metaplasia in Helicobacter pylori infection: the role of CagA status. Am J Gastroenterol 93:375–379
Sakata I, Tanaka T, Yamazaki M, Tanizaki T, Zheng Z, Sakai T (2006) Gastric estrogen directly induces ghrelin expression and production in the rat stomach. J Endocrinol 190:749–757
Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H et al (2005) Ghrelin directly regulates bone formation. J Bone Miner Res 20:790–798
Weiss LA, Langenberg C, Barrett-Connor E (2006) Ghrelin and bone: is there an association in older adults? The Rancho Bernardo Study. J Bone Miner Res 21:752–757
Dobigny C, Saffar JL (1997) H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol 173:10–18
Lesclous P, Guez D, Saffar JL (2002) Short-term prevention of osteoclastic resorption and osteopenia in ovariectomized rats treated with the H2 receptor antagonist cimetidine. Bone 30:131–136
Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S (1998) Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 62:283–285
Grisso JA, Kelsey JL, O’Brien LA, Miles CG, Sidney S, Maislin G et al (1997) Risk factors for hip fracture in men Hip Fracture Study Group. Am J Epidemiol 145:786–793
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326
de Vries F, Cooper A, Logan R, Cockle S, van Staa T, Cooper C (2007) Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonate alone. Osteoporos Int 18(Suppl 3):S261
Acknowledgements
We acknowledge the contributions of the other members of the OPUS teams at the five participating centers: Rosie Reid, Lana Gibson, and Alison Stewart in Aberdeen; Antonia Gerwinn, Dr. Maren Glüer, Roswitha John, Roswitha Marunde-Ott, Monika Mohr, Regina Schlenger, Pia Zschoche, Dr. Reinhard Barkmann, Dr. Carsten Liess, Carsten Rose, and Wolfram Timm in Kiel; Therese Kolta and Nathalie Delfau in Paris; Margaret Paggiosi, Nicky Peel, Diane Shutt, Anne Stapleton, and Debbie Swindell in Sheffield. This project would not have been possible without the financial support of our sponsors: Aventis, Eli Lilly, Novartis, Procter & Gamble Pharmaceuticals, and Roche. We also thank the equipment manufacturers: DMS, IGEA, OSI/Osteometer Meditech, Quidel/metra.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roux, C., Briot, K., Gossec, L. et al. Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole. Calcif Tissue Int 84, 13–19 (2009). https://doi.org/10.1007/s00223-008-9188-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-008-9188-4